| scholarly article | Q13442814 |
| P50 | author | Giuseppe Ippolito | Q28468788 |
| Concetta Castilletti | Q28743724 | ||
| Licia Bordi | Q51983623 | ||
| Chiara Agrati | Q55456343 | ||
| Massimo Tempestilli | Q56424237 | ||
| P2093 | author name string | Cristiana Gioia | |
| Fabrizio Poccia | |||
| Maria R Capobianchi | |||
| Paola Piacentini | |||
| Roberta Chiappini | |||
| Salvatore Squarcione | |||
| Vincenzo Puro | |||
| P2860 | cites work | Influenza pandemics of the 20th century | Q22305643 |
| Avian Influenza A (H5N1) Age Distribution in Humans | Q24676937 | ||
| Global epidemiology of influenza: past and present. | Q30326723 | ||
| Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. | Q30352066 | ||
| Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. | Q30359842 | ||
| Human cytotoxic T-lymphocyte repertoire to influenza A viruses | Q33785232 | ||
| Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets | Q33864980 | ||
| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans | Q34361636 | ||
| T cell-dependent B cell activation | Q34363600 | ||
| Trends and epidemics of influenza and pneumonia: 1918-1951 | Q36073154 | ||
| Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species | Q39509861 | ||
| Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus | Q39584981 | ||
| The immune response to influenza infection | Q39745451 | ||
| Immunity to influenza in man | Q40162453 | ||
| Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. | Q40191487 | ||
| Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice | Q40742933 | ||
| Laboratory security and emergency response guidance for laboratories working with select agents. Centers for Disease Control and Prevention | Q42037827 | ||
| An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions | Q42105732 | ||
| Community-acquired influenza C virus infection in children | Q43207683 | ||
| Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. | Q43209654 | ||
| Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity | Q44189242 | ||
| Virus-specific CD8+ T cells in primary and secondary influenza pneumonia | Q45755057 | ||
| Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice | Q45793556 | ||
| T-Cell response profiling to biological threat agents including the SARS coronavirus | Q46705027 | ||
| Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza? | Q71547317 | ||
| T cell anergy | Q71999397 | ||
| CD4+ T-cell induction and effector functions: a comparison of immunity against soluble antigens and viral infections | Q77355825 | ||
| CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection | Q81375555 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | infectious disease | Q18123741 |
| avian influenza | Q43987 | ||
| P304 | page(s) | 121-8 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Emerging Infectious Diseases | Q5235761 |
| P1476 | title | Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza | |
| P478 | volume | 14 |
| Q39397313 | A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus |
| Q36731466 | A novel M2e-multiple antigenic peptide providing heterologous protection in mice |
| Q30396693 | A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults |
| Q30384441 | Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. |
| Q30424161 | Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza |
| Q30383882 | Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people. |
| Q30394896 | Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults |
| Q36151974 | Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine |
| Q30366119 | Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects. |
| Q30414543 | Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients |
| Q37478636 | Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. |
| Q36075789 | Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. |
| Q57158300 | Correlates of Protection Against Influenza |
| Q30400133 | Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus |
| Q30373391 | Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and direct |
| Q30363454 | Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. |
| Q36611283 | Cross-reactivity between avian influenza A (H7N9) virus and divergent H7 subtypic- and heterosubtypic influenza A viruses |
| Q30403078 | Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study |
| Q30429009 | Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial |
| Q21090975 | Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP |
| Q34613129 | Evidence that life history characteristics of wild birds influence infection and exposure to influenza A viruses |
| Q37398991 | Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases |
| Q41498948 | H5N1 strain-specific hemagglutinin CD4+ T cell epitopes restricted by HLA DR4. |
| Q21090076 | H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines |
| Q36251479 | Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza |
| Q30401524 | Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus |
| Q30388038 | Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine |
| Q30373729 | Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. |
| Q34792746 | Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer |
| Q49125030 | Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults |
| Q38111876 | Immune responses to infection with H5N1 influenza virus |
| Q37030332 | Immunogenetics of seasonal influenza vaccine response |
| Q30401306 | Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial |
| Q39503548 | Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus |
| Q37778053 | Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly |
| Q30425194 | Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice |
| Q30401056 | Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. |
| Q40138342 | M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza |
| Q30374764 | MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults |
| Q30425439 | Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine |
| Q30377856 | Pandemic influenza: impact on perianesthesia nursing areas. |
| Q56880027 | Passive immunization with influenza haemagglutinin specific monoclonal antibodies |
| Q30430737 | Population-level antibody estimates to novel influenza A/H7N9. |
| Q43499342 | Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. |
| Q30426571 | Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination |
| Q41497402 | Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies |
| Q33511049 | Protective measures and H5N1-seroprevalence among personnel tasked with bird collection during an outbreak of avian influenza A/H5N1 in wild birds, Ruegen, Germany, 2006 |
| Q57111038 | Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009 |
| Q30410983 | Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly |
| Q30376727 | Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies |
| Q30389669 | Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel |
| Q82276734 | Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination |
| Q30403507 | Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans |
| Q34869353 | Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial |
| Q30418193 | Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada |
| Q51164439 | The persistence of multiple strains of avian influenza in live bird markets. |
| Q30368645 | The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study |
| Q28075317 | Weighing serological evidence of human exposure to animal influenza viruses - a literature review |
| Q34756837 | Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies |
Search more.